Dr Reddy launches Lansoprazole Delayed-Release capsules in US

Hyderabad based pharma major Dr. Reddy's Laboratories has announced the launch of Lansoprazole Delayed-Release Capsules USP, 15 mg, an over-the-counter (OTC) store-brand equivalent of Prevacid 24HR Capsules, in the United States market, as approved by the USFDA on Monday.

The said medicine is used to treat or prevent GI (gastrointestinal) ulcers caused by infection. Company’s OTC Lansoprazole Delayed-Release Capsules USP, 15 mg, are available in 14, 28 and 42 count sizes.

As per IRi health data, Prevacid 24HR Capsules had sales of around US$ 57 million dollar MAT for the 12-month period ending August 2019 in US markets.

Milan Kalawadia, Senior Vice President and Head of US OTC and Specialty Rx Divisions, Dr. Reddy's Laboratories said – “We are pleased to continue to expand our antacids and PPI portfolio for our customers. We look forward to collaborating with our customers to provide high-quality, affordable alternatives to consumers."

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

On Monday, the stock of Dr.Reddy's Laboratories opened at Rs. 2731.95 and made an intraday high and low of Rs. 2762 and Rs. 2703.75 respectively on the BSE. At 12:10, the stock was trading nearly at Rs. 2728.75 on the BSE.